Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 7/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436684 | 0.86 | CDC7 (0.44) | MAPTTP53LMNATHRB | |
| SCHEMBL3436694 | 0.85 | KDM4E (0.43) | MAPTTP53LMNA | |
| SCHEMBL3438288 | 0.85 | DCK (0.36) | MAPTTP53HDAC9TLR8 | |
| SCHEMBL19936517 | 0.83 | FFAR1 (0.39) | MAPTTP53LMNAFFAR1PPARD | |
| SCHEMBL3436690 | 0.82 | KDM4E (0.42) | MAPTTP53LMNATHRB | |
| SCHEMBL6842692 | 0.79 | TP53 (0.39) | MAPTTP53LMNAFFAR1PPARD | |
| SCHEMBL279517 | 0.79 | LMNA (0.39) | MAPTTP53LMNATHRB | |
| SCHEMBL3436689 | 0.78 | TRPM8 (0.41) | MAPTTP53LMNAFFAR1PPARD | |
| SCHEMBL14960141 | 0.77 | TLR8 (0.39) | MAPTHDAC9TLR8 | |
| SCHEMBL19936382 | 0.76 | HDAC9 (0.39) | MAPTLMNAHDAC9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| WO-2012002527-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | あすか製薬株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | MAPT 4033/4885TP53 86/4885LMNA 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.